Probiotics and prevention of Clostridium difficile infection

被引：30

作者：

Goldstein, E. J. C. ^{[1
,2
]}

Johnson, S. J. ^{[3
]}

Maziade, P. -J. ^{[4
]}

Evans, C. T. ^{[5
,6
,7
]}

Sniffen, J. C. ^{[8
]}

Millette, M. ^{[9
]}

McFarland, L. V. ^{[10
]}

机构：

[1] RM Alden Res Lab, Santa Monica, CA USA

[2] Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA

[3] Loyola Sch Med, Chicago, IL USA

[4] Pierre Le Gardeur Hosp, Terrebonne, PQ, Canada

[5] Northwestern Univ, Dept Prevent Med, Chicago, IL 60611 USA

[6] Northwestern Univ, Ctr Healthcare Studies, Chicago, IL 60611 USA

[7] Edward Hines Jr VA Hosp, Chicago, IL USA

[8] Florida Hosp, Orlando, FL USA

[9] BioK Plus Int Inc, Laval, PQ, Canada

[10] Univ Washington, Dept Med Chem, Seattle, WA 98195 USA

来源：

ANAEROBE | 2017年 / 45卷

关键词：

Probiotic; Bio-K; Saccharomyces boulardii; C; difficile; Lactobacillus rhamnosus GG; Lactobacillus acidophilus CL1285; Lactobacillus casei LBC80R; Lactobacillus rhamnosus CLR2; LACTOBACILLUS-ACIDOPHILUS CL1285; ANTIBIOTIC-ASSOCIATED DIARRHEA; CASEI LBC80R; COST-EFFECTIVENESS; DOUBLE-BLIND; COMBINATION; EPIDEMIOLOGY; INPATIENTS; SURVIVAL; RELAPSE;

D O I：

10.1016/j.anaerobe.2016.12.007

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

The role of probiotics as adjunctive measures in the prevention of Clostridium difficile infection (CDI) has been controversial. However, a growing body of evidence has suggested that they have a role in primary prevention of CDI. Elements of this controversy are reviewed and the proposed mechanisms of action, the value and cost effectiveness of probiotics are addressed with a focus on three agents, Saccharomyces boulardii, Lactobacillus rhamnosus GG and the combination of Lactobacillus acidophilus CL1285, Lactobacillus casei LBC8OR, Lactobacillus rhamnosus CLR2 (Bio-K+). (C) 2016 Elsevier Ltd. All rights reserved.

引用

页码：114 / 119

页数：6

共 50 条

[31] Cost-Effectiveness Analysis of Six Strategies to Treat Recurrent Clostridium difficile Infection [J].

Lapointe-Shaw, Lauren ;

Tran, Kim L. ;

Coyte, Peter C. ;

Hancock-Howard, Rebecca L. ;

Powis, Jeff ;

Poutanen, Susan M. ;

Hota, Susy .

PLOS ONE, 2016, 11 (02)

[32] Cost-Effectiveness Analysis of the Use of Probiotics for the Prevention of Clostridium difficile-Associated Diarrhea in a Provincial Healthcare System [J].

Leal, Jenine R. ;

Heitman, Steven J. ;

Conly, John M. ;

Henderson, Elizabeth A. ;

Manns, Braden J. .

INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY, 2016, 37 (09) :1079-1086

[33] A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality [J].

Loo, VG ;

Poirier, L ;

Miller, MA ;

Oughton, M ;

Libman, MD ;

Michaud, S ;

Bourgault, AM ;

Nguyen, T ;

Frenette, C ;

Kelly, M ;

Vibien, A ;

Brassard, P ;

Fenn, S ;

Dewar, K ;

Hudson, TJ ;

Horn, R ;

René, P ;

Monczak, Y ;

Dascal, A .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (23) :2442-2449

[34] Impact of adding prophylactic probiotics to a bundle of standard preventative measures for Clostridium difficile infections: enhanced and sustained decrease in the incidence and severity of infection at a community hospital [J].

Maziade, P-J ;

Andriessen, J. A. ;

Pereira, P. ;

Currie, B. ;

Goldstein, E. J. C. .

CURRENT MEDICAL RESEARCH AND OPINION, 2013, 29 (10) :1341-1347

[35] A Decade of Experience in Primary Prevention of Clostridium difficile Infection at a Community Hospital Using the Probiotic Combination Lactobacillus acidophilus CL1285, Lactobacillus casei LBC80R, and Lactobacillus rhamnosus CLR2 (Bio-K+) [J].

Maziade, Pierre-Jean ;

Pereira, Pascale ;

Goldstein, Ellie J. C. .

CLINICAL INFECTIOUS DISEASES, 2015, 60 :S144-S147

[36] RANDOMIZED PLACEBO-CONTROLLED TRIAL OF SACCHAROMYCES-BOULARDII IN COMBINATION WITH STANDARD ANTIBIOTICS FOR CLOSTRIDIUM-DIFFICILE DISEASE [J].

MCFARLAND, LV ;

SURAWICZ, CM ;

GREENBERG, RN ;

FEKETY, R ;

ELMER, GW ;

MOYER, KA ;

MELCHER, SA ;

BOWEN, KE ;

COX, JL ;

NOORANI, Z ;

HARRINGTON, G ;

RUBIN, M ;

GREENWALD, D .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1994, 271 (24) :1913-1918

[37] An observation on inappropriate probiotic subgroup classifications in the meta-analysis by Lau and Chamberlain [J].

McFarland, Lynne V. .

INTERNATIONAL JOURNAL OF GENERAL MEDICINE, 2016, 9 :333-335

[38] From Yaks to Yogurt: The History, Development, and Current Use of Probiotics [J].

McFarland, Lynne V. .

CLINICAL INFECTIOUS DISEASES, 2015, 60 :S85-S90

[39] Evidence-based review of probiotics for antibiotic-associated diarrhea and Clostridium difficile infections [J].

McFarland, Lynne V. .

ANAEROBE, 2009, 15 (06) :274-280

[40] Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada [J].

Pépin, J ;

Alary, ME ;

Valiquette, L ;

Raiche, E ;

Ruel, J ;

Fulop, K ;

Godin, D ;

Bourassa, C .

CLINICAL INFECTIOUS DISEASES, 2005, 40 (11) :1591-1597

← 1 2 3 4 5 →